AUSTIN, Texas, Nov. 16 /PRNewswire-FirstCall/ -- Introgen Therapeutics,
Inc. (Nasdaq: INGN) announced today that it has obtained the exclusive,
worldwide license to a portfolio of patents from The University of Texas M.
D. Anderson Cancer Center focused on the delivery of biologically active
proteins, polypeptides and peptides using novel nanoparticle delivery
complexes. The technology has demonstrated substantial therapeutic efficacy
against human lung cancers in animal models. The systemically-delivered
nanoparticles are applicable to a wide variety of bioactive protein-derived
The licensed technology is directed to specially designed nanoparticles
that carry and deliver therapeutic bioactive proteins, polypeptides and
peptides to targeted cells, such as cancer cells. These nanoparticle
formulations have certain therapeutic advantages. While peptides alone may
be rapidly removed from circulation, requiring frequent administration and
high doses, Introgen's nanoparticle-polypeptide formulations can increase
therapeutic activity and protect against rapid degradation normally
associated with peptide therapy. In addition, Introgen's peptide
nanoparticles can include special targeting molecules to further enhance
cellular uptake and to improve therapeutic efficacy.
"Acquiring rights to these nanoparticle delivery technologies
represents a significant addition to Introgen's drug delivery platforms,"
said David G. Nance, Introgen's Chief Executive Officer. "While our
existing programs include nanoparticle delivery of tumor suppressor genes,
the new technology expands our capabilities to include delivery of
therapeutic peptides and polypeptides as well as proteins. We expect these
technologies to enable important advances in the targeted delivery of a
variety of therapeutic biologics."
Introgen currently has three therapeutic nanoparticle product
candidates: INGN 401 (nanoparticle FUS-1), INGN 402 (nanoparticle p53) and
INGN 403 (nanoparticle mda-7). INGN 401 is currently in phase 1 clinical
testing for metastatic lung cancer.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on
the discovery, development and commercialization of targeted molecular
therapies for the treatment of cancer and other diseases. Introgen is
developing molecular therapeutics, immunotherapies, vaccines and
nanoparticle therapies to treat a wide range of cancers using tumor
suppressors and cytokines. Introgen maintains integrated research,
development, manufacturing, clinical and regulatory departments and
operates multiple manufacturing facilities including a commercial scale
cGMP manufacturing facility.
Introgen holds license agreements with M. D. Anderson Cancer Center to
commercialize products based on licensed technologies, and has the option
to license future technologies under sponsored research agreements. The
University of Texas Board of Regents owns stock in Introgen. These
arrangements are managed in accordance with M. D. Anderson's conflict of
Statements in this release that are not strictly historical may be
"forward-looking" statements, including those relating to Introgen's future
success with its nanoparticle delivery systems and clinical programs for
the treatment of cancer or other diseases. The actual results may differ
from those described in this release due to risks and uncertainties that
exist in Introgen's operations and business environment, including
Introgen's stage of product development and the limited experience in the
development of protein- based drugs in general, dependence upon proprietary
technology and the current competitive environment, history of operating
losses and accumulated deficits, reliance on collaborative relationships,
and uncertainties related to clinical trials, the safety and efficacy of
Introgen's product candidates, the ability to obtain the appropriate
regulatory approvals, Introgen's patent protection and market acceptance,
as well as other risks detailed from time to time in Introgen's filings
with the Securities and Exchange Commission, including its filings on Form
10-K and Form 10-Q. Introgen undertakes no obligation to publicly release
the results of any revisions to any forward-looking statements that reflect
events or circumstances arising after the date hereof.
Editor's Note: For more information on Introgen Therapeutics, or for a
menu of archived press releases, please visit Introgen's Website at:
Contact: Introgen Therapeutics, Inc.
C. Channing Burke
(512)708 9310 Ext. 322
SOURCE Introgen Therapeutics, Inc.